Loading ...
Chemotherapy - induced thrombocytopeniacan leadto chemotherapy treatment delays
secondary cytoreductive surgerycauseschemotherapy delays and/or
etcleadingto chemotherapy delays
cancer treatmentcausingchemotherapy delays
by drug resistance and the other part of patients(passive) caused bychemotherapy failure
drug resistance and the other part of patients(passive) caused bychemotherapy failure
by MDR , which occurs during the course of cancer progression and chemotherapy(passive) caused bychemotherapy failure
by multidrug resistance in lung tumor cells(passive) caused bychemotherapy failure
delay in initial assessment by the nurse ... identifiedleadingto delay in chemotherapy
surgical complicationsleadto delay in chemotherapy
the only factor identifiedleadingto delay in chemotherapy
identifiedleadingto delay in chemotherapy
one timecausinga delay in chemotherapy
any doctors herecould causea delay on chemo
the determinants of delayed adjuvant chemotherapy ... the postoperative complicationsresultedin chemotherapy delay
A platelet count that is below 100,000can already causethe delay of the chemotherapy
to kill fast - growing cells(passive) are designedChemotherapy Chemotherapeutics
to prevent the recurrence of cancer(passive) is mainly designedAdjuvant chemotherapy
to prevent recurrence of the disease , particularly distant recurrence(passive) is designedAdjuvant chemotherapy
to kill quickly dividing cells(passive) is designedChemotherapy
to kill fast - growing cells(passive) is designedChemotherapy
the factorsinfluencingneoadjuvant chemotherapy
to kill rapidly dividing cancer cells(passive) is designedChemotherapy Chemotherapy
to kill rapidly growing cells such as cancer cells but affects all rapidly growing cells(passive) is designedChemotherapy
to kill fast - growing cancer cells(passive) is designedChemotherapy
the P - gp cells(passive) caused bychemotherapy
to target rapidly dividing cells in a specific stage of cell division(passive) is designedChemotherapy
to kill rapidly dividing cells throughout the body(passive) is designedChemotherapy
to kill cancer cells(passive) is designedChemotherapy
to kill fast - growing cells , like cancer cells(passive) is designedChemotherapy
before surgery(passive) has ... been discoveredNeoadjuvant chemotherapy
to destroy the rapidly dividing cells(passive) is designedChemotherapy
to kill fast dividing cells(passive) is designedChemotherapy
Multimodal treatment including surgical resection , radiotherapy , andhas ledchemotherapy
to kill tumor cells(passive) is designedChemotherapy
to attack cells that are growing and multiplying(passive) is designedChemotherapy
to kill cancerous cells(passive) is designedChemotherapy
to treat your whole body in an attempt to destroy cancer cells(passive) is designedChemotherapy
poststenotic pneumonia without leucocytopenia or neutropenia(passive) caused bysequential chemotherapy
a cellcausedchemotherapy , out
a range of side effectscausinga range of side effects
in reduced relative dose intensity ( RDIresultingin reduced relative dose intensity ( RDI
in reduced relative dose intensity ( RDI ) andresultingin reduced relative dose intensity ( RDI ) and
in tumor lysis and elevation of plasmato resultin tumor lysis and elevation of plasma
to worse disease - free and overall survivalleadto worse disease - free and overall survival
in reduced relative dose intensity ( RDI ) and leading to less effective chemotherapy , impacting negatively on patient outcomes [ 3 , 4resultingin reduced relative dose intensity ( RDI ) and leading to less effective chemotherapy , impacting negatively on patient outcomes [ 3 , 4
cell damage and cell death(passive) caused bycell damage and cell death
in prolonged myelosuppression , including patients undergoing blood and marrow transplantationresultingin prolonged myelosuppression , including patients undergoing blood and marrow transplantation
the treatmentcould influence how wellthe treatment
survival in patients withcould influencesurvival in patients with
survival in patientscould influencesurvival in patients
to longer survival among patients with early breast cancerledto longer survival among patients with early breast cancer
to better survival outcomeleadingto better survival outcome
in only modest prolongation of survival for patients with lung cancerhas resultedin only modest prolongation of survival for patients with lung cancer
in worse outcome of TNBC patientscould resultin worse outcome of TNBC patients
to survivalcontributedto survival
to survival in high - risk stage II patientsdid ... contributeto survival in high - risk stage II patients
to longer survivalmay contributeto longer survival
to the recurrence of the tumorledto the recurrence of the tumor
in patientscould influencein patients
the patientsmay influencethe patients
to an increased risk for metabolic syndrome in patients with breast cancermay contributeto an increased risk for metabolic syndrome in patients with breast cancer
to survivaldid ... contributeto survival
to survivalcontributesto survival
to shrink the cancer before surgeryis designedto shrink the cancer before surgery
in statistically significant improvement in disease - free survivalresultedin statistically significant improvement in disease - free survival
to an increased risk for metabolic syndrome in breast cancer patients and these changes are more profound in pre - menopausal patientsmay contributeto an increased risk for metabolic syndrome in breast cancer patients and these changes are more profound in pre - menopausal patients
in worse outcome of TNBC patients , especially node positive onescould resultin worse outcome of TNBC patients , especially node positive ones
to improving survival in some subgroupscan contributeto improving survival in some subgroups
to such improvementcontributedto such improvement
ovarian failuremay causeovarian failure
the choice of chemotherapy for the treatment of metachronous metastasesinfluencedthe choice of chemotherapy for the treatment of metachronous metastases
to the patient 's deathledto the patient 's death
outcomeinfluencedoutcome
significantlycontributessignificantly
to an improvement in both local and distant recurrence with a corresponding improvement in overall survival while chemoradiation only led to an improvement in local recurrence but not distant nor overall survivalledto an improvement in both local and distant recurrence with a corresponding improvement in overall survival while chemoradiation only led to an improvement in local recurrence but not distant nor overall survival
the resultscould influencethe results
in rapid bone lossresultsin rapid bone loss
in significant improvement in patient survivalresultedin significant improvement in patient survival
to improved survivalwould leadto improved survival